Search research articles
Contact Us
Filters
Showing results (471-480 of 542) with videos related to
Page
of 55
Sort By:
The Journal of Infectious Diseases
|
October 1, 1996
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group
M E Brandt, M A Pfaller, R A Hajjeh, et al.
Diagnostic Microbiology and Infectious Disease
|
October 9, 1998
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel
M A Pfaller, S A Messer, R J Hollis, et al.
Journal of Clinical Microbiology
|
July 1, 1997
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection
S W Redding, M A Pfaller, S A Messer, et al.
Antimicrobial Agents and Chemotherapy
|
October 16, 2001
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998
M E Brandt, M A Pfaller, R A Hajjeh, et al.
Antimicrobial Agents and Chemotherapy
|
May 30, 2013
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method
A Espinel-Ingroff, A Chowdhary, G M Gonzalez, et al.
Journal of Clinical Microbiology
|
December 8, 2005
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing
M A Pfaller, D J Diekema, M G Rinaldi, et al.
Journal of Clinical Microbiology
|
February 19, 2010
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion
M A Pfaller, D J Diekema, D L Gibbs, et al.
Journal of Clinical Microbiology
|
November 20, 2009
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp
M A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology
|
January 18, 2008
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005
M A Pfaller, D J Diekema, D L Gibbs, et al.
Journal of Clinical Microbiology
|
May 4, 2007
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds
A Espinel-Ingroff, A Fothergill, M Ghannoum, et al.
Page
of 55
Search research articles
Search
Showing results (471-480 of 542) with videos related to
Sort By:
Page
of 55
The Journal of Infectious Diseases
|
October 1, 1996
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group
M E Brandt, M A Pfaller, R A Hajjeh, et al.
Diagnostic Microbiology and Infectious Disease
|
October 9, 1998
Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel
M A Pfaller, S A Messer, R J Hollis, et al.
Journal of Clinical Microbiology
|
July 1, 1997
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection
S W Redding, M A Pfaller, S A Messer, et al.
Antimicrobial Agents and Chemotherapy
|
October 16, 2001
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998
M E Brandt, M A Pfaller, R A Hajjeh, et al.
Antimicrobial Agents and Chemotherapy
|
May 30, 2013
Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method
A Espinel-Ingroff, A Chowdhary, G M Gonzalez, et al.
Journal of Clinical Microbiology
|
December 8, 2005
Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing
M A Pfaller, D J Diekema, M G Rinaldi, et al.
Journal of Clinical Microbiology
|
February 19, 2010
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion
M A Pfaller, D J Diekema, D L Gibbs, et al.
Journal of Clinical Microbiology
|
November 20, 2009
Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp
M A Pfaller, L Boyken, R J Hollis, et al.
Journal of Clinical Microbiology
|
January 18, 2008
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005
M A Pfaller, D J Diekema, D L Gibbs, et al.
Journal of Clinical Microbiology
|
May 4, 2007
Quality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds
A Espinel-Ingroff, A Fothergill, M Ghannoum, et al.
Page
of 55